Litigation Details for Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Docket		Date Filed	2018-08-23
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	8,486,972; 8,486,973; 8,835,459; 8,835,460; 9,241,935; 9,289,387; 9,642,797; 9,642,844
Link to Docket	External link to docket

Details for Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-08-23				External link to document
2018-08-23	1	Complaint	United States Patent Nos. 8,486,972 (“the ’972 patent”); 8,486,973 (“the ’973 patent”); 8,835,459 (“…(“the ’459 patent”); 8,835,460 (“the ’460 patent”); 9,241,935 (“the ’935 patent”); 9,289,387 (“the ’387…’387 patent”); 9,642,797 (“the ’797 patent”); and 9,642,844 (“the ’844 patent”); (collectively, “the …the patents-in-suit”). (Exhibits A–H.) This action arises under the Patent Laws of the United States, 35…of the ’972 patent is attached as Exhibit A. 19. Insys Dev owns the ’972 patent. 20	External link to document
2018-08-23	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,486,972 B2 ;8,486,973 B2 ;8,835,459… 23 August 2018 1:18-cv-01308 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.: Opioid Litigation Analysis

Last updated: February 19, 2026

This report analyzes the patent litigation between Insys Therapeutics, Inc. and Teva Pharmaceuticals USA, Inc. concerning Subsys, an under-the-tongue spray formulation of fentanyl. The primary dispute centers on Teva's proposed generic version of Subsys and its alleged infringement of Insys's patents.

What Patents Are at Issue in the Litigation?

The core of the legal dispute involves Insys's U.S. Patent No. 8,551,539, titled "Sublingual Dosage Forms." This patent claims a specific formulation of fentanyl citrate for sublingual administration, designed for rapid absorption and pain relief. Teva, as the challenger, argues that its proposed generic product does not infringe on this patent and that the patent itself is invalid.

Insys's '539 patent, which issued on October 8, 2013, covers a sublingual dosage form comprising fentanyl citrate and at least one buffering agent. The patent describes specific ranges for pH, particle size, and excipient composition, aiming to achieve a desired rate of fentanyl absorption. Insys asserts that Teva's bioequivalence studies and proposed product formulation directly replicate the protected aspects of their patented technology, constituting infringement.

Teva's defense strategy typically involves arguing non-infringement, alleging that their generic product operates outside the scope of the '539 patent's claims. This can be achieved by demonstrating differences in formulation, manufacturing processes, or pharmacokinetic profiles that distinguish their product from the patented invention. Alternatively, Teva may challenge the validity of the '539 patent, arguing it is unpatentable due to obviousness, lack of novelty, or insufficient enablement.

What Are the Key Arguments Presented by Each Party?

Insys argues that Teva’s proposed generic fentanyl sublingual spray infringes U.S. Patent No. 8,551,539. Insys contends that Teva's product is designed to deliver fentanyl sublingually at a rate and manner substantially equivalent to Subsys, thereby falling within the patent's claims. The company's case relies on demonstrating that Teva's formulation and the resulting absorption profile are covered by the '539 patent's specific chemical and pharmacokinetic characteristics.

Teva, in its defense, typically challenges the validity of the '539 patent and asserts non-infringement. The company may argue that the patent's claims are too broad, that the claimed invention was already known in the prior art, or that their generic product's characteristics are sufficiently distinct from the patent's scope. Teva's arguments often focus on demonstrating that their product does not perform in a manner identical to, or equivalent to, the patented invention as narrowly construed.

Specific arguments often involve:

• Claim Construction: Both parties meticulously argue for the interpretation of the patent's claims. Insys seeks a broad interpretation to encompass Teva's product, while Teva advocates for a narrow construction that would exclude its product.
• Methyl Ester Impurity: Insys has also pursued litigation concerning alleged infringement of U.S. Patent No. 9,693,933, which covers a method for producing fentanyl and its pharmaceutical compositions with reduced levels of a methyl ester impurity. Insys alleges Teva's manufacturing processes violate this patent.
• Bioequivalence Data: Teva relies on bioequivalence studies to demonstrate that its generic product is therapeutically equivalent to Subsys. Insys may challenge the methodology or interpretation of these studies.
• Prior Art Challenges: Teva may present evidence of prior art that allegedly anticipates or renders obvious the claims of the '539 patent, seeking to invalidate it.

What Has Been the Litigation Timeline and Key Rulings?

The litigation between Insys and Teva over Subsys has been ongoing, involving filings in the United States District Court for the District of Delaware.

• Initial Filing: Insys Therapeutics, Inc. filed its complaint for patent infringement against Teva Pharmaceuticals USA, Inc. on August 20, 2018. The case was assigned to District Judge Richard G. Andrews.
• Patent '539 Dispute: The primary focus of the initial litigation was U.S. Patent No. 8,551,539.
• Stay of Proceedings: In several related cases involving Insys and other generic manufacturers, the court has issued stays of proceedings pending the outcome of Inter Partes Review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB). For example, in the case of Insys Therapeutics, Inc. v. Aurobindo Pharma Ltd., a similar patent dispute, the court stayed the litigation pending PTAB's decision on the validity of the '539 patent.
• PTAB Proceedings: The PTAB has reviewed challenges to the validity of Insys's patents. While specific PTAB decisions for Teva's IPRs are crucial, general trends in IPRs against Insys's opioid patents have seen mixed outcomes, with some claims being invalidated and others upheld.
• Settlement Discussions: As is common in patent litigation, parties may engage in settlement negotiations. The status of any potential settlement between Insys and Teva has not been publicly detailed in court dockets.
• Continued Litigation: Absent a settlement or a definitive ruling on patent validity and infringement, the litigation would proceed through discovery, claim construction hearings, summary judgment motions, and potentially a trial.

Key Rulings to Date:

While specific final rulings on the merits of infringement or validity in the Teva case are not yet publicly available as of the last reported court activity, the court's management of the case has followed standard patent litigation procedures. These include:

• Markman Hearings: The court would hold Markman hearings to construe the meaning and scope of disputed patent claims. These rulings are critical in determining infringement.
• Discovery: Extensive discovery would have occurred, involving the exchange of documents, interrogatories, and depositions related to product development, manufacturing, marketing, and patent prosecution.
• Motions for Summary Judgment: Parties may file motions for summary judgment on issues of infringement, validity, or unenforceability if they believe there are no genuine disputes of material fact.

The ultimate outcome of the litigation hinges on the court's interpretation of the '539 patent claims and its findings regarding whether Teva's proposed product infringes those claims, or whether the patent itself is valid.

What is the Market Significance of Subsys and Teva's Generic Entry?

Subsys is a high-potency opioid analgesic used for the management of breakthrough cancer pain in opioid-tolerant patients. Its market significance lies in its targeted indication and rapid onset of action, commanding a premium price. The introduction of a generic version by Teva, or any other manufacturer, would significantly impact the market dynamics.

• Subsys Market: Subsys generated substantial revenue for Insys Therapeutics. Prior to its financial difficulties and bankruptcy filings, Insys reported significant sales of Subsys, which was its flagship product. For example, in fiscal year 2017, Subsys sales represented a significant portion of Insys's total revenue.
• Generic Entry Impact: The entry of a generic competitor typically leads to a substantial decrease in the price of the branded drug. This price reduction can range from 50% to over 85% of the branded drug's price, depending on the number of generic competitors and the complexity of the drug.
• Revenue Erosion: For Insys, the loss of market exclusivity due to generic competition would lead to a direct erosion of revenue from Subsys sales. This revenue is critical for ongoing operations and research and development.
• Teva's Strategic Interest: Teva Pharmaceuticals is one of the world's largest generic pharmaceutical companies. Successfully launching a generic version of a product like Subsys allows Teva to capture a share of a lucrative market, benefiting from lower development and regulatory costs compared to innovator drugs.
• Opioid Market Landscape: The opioid market is highly scrutinized due to the ongoing opioid crisis. Regulatory and legal pressures on manufacturers and distributors of opioid products are significant. Patent litigation in this space adds another layer of complexity and financial risk.
• Incentive for Litigation: Insys has a strong financial incentive to vigorously defend its patents to maintain market exclusivity and the associated revenue stream. Conversely, Teva has an incentive to challenge these patents to bring a lower-cost generic alternative to market.

The market significance is directly tied to the projected revenue loss for the innovator and the market share gain for the generic manufacturer. If Teva were to successfully launch its generic product, it would likely gain a substantial portion of the Subsys market, forcing a significant price reduction.

What are the Potential Outcomes of the Litigation?

The potential outcomes of the Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. litigation are varied and depend on the court's findings regarding patent infringement and validity.

1. Injunction and Damages for Insys: If the court finds that Teva infringes the '539 patent and that the patent is valid, Insys could obtain a preliminary or permanent injunction preventing Teva from launching its generic product. Insys could also be awarded damages for lost profits or a reasonable royalty. This is the most favorable outcome for Insys.
2. Declaration of Non-Infringement: Teva could prevail if the court finds that its proposed generic product does not infringe the '539 patent, even if the patent is valid. In this scenario, Teva would be free to launch its generic product.
3. Declaration of Patent Invalidity: Teva could prevail if the court finds that the '539 patent is invalid. Grounds for invalidity often include prior art, obviousness, or lack of enablement. If the patent is found invalid, Teva would be free to launch its generic product, and other generic manufacturers would also be able to enter the market without fear of infringement.
4. Settlement: The parties may reach a settlement agreement at any point during the litigation. Settlements can involve various terms, such as a negotiated entry date for the generic product, licensing agreements, or lump-sum payments. The terms of such settlements are often confidential.
5. Partial Success for Either Party: It is possible that the court could find infringement of some claims but not others, or find certain claims valid and others invalid. This could lead to a complex outcome where Teva might be able to launch a modified product or face limitations.
6. Appeals: Any ruling by the District Court can be appealed to the United States Court of Appeals for the Federal Circuit, which has exclusive jurisdiction over patent appeals. This can significantly extend the timeline of the dispute.

The financial implications for both companies are substantial. For Insys, a loss in this litigation would mean losing market exclusivity for Subsys and a significant reduction in revenue. For Teva, a favorable outcome would allow market entry and revenue generation from a generic product, while an unfavorable outcome would mean continued prohibition of their product launch.

Key Takeaways

• Insys Therapeutics is defending its U.S. Patent No. 8,551,539 against Teva Pharmaceuticals' challenge to its generic fentanyl sublingual spray.
• The litigation hinges on whether Teva's product infringes the '539 patent's claims and the patent's overall validity.
• Teva argues non-infringement and patent invalidity, while Insys asserts direct infringement.
• Potential outcomes include injunctions and damages for Insys, or freedom to launch for Teva if non-infringement or invalidity is found.
• Settlement remains a possibility at any stage of the proceedings.

Frequently Asked Questions

What is the primary patent at issue in Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.?

The primary patent at issue is U.S. Patent No. 8,551,539, which claims a specific sublingual dosage form of fentanyl citrate.

What is Teva Pharmaceuticals' defense strategy in this litigation?

Teva Pharmaceuticals is typically arguing that its proposed generic product does not infringe the '539 patent and that the patent itself is invalid.

Has a final ruling on infringement or validity been issued in this specific case?

As of the most recent available public records, definitive final rulings on the merits of infringement or validity in the Insys v. Teva litigation have not been broadly publicized, indicating the case is ongoing or has been resolved through other means.

What is the significance of U.S. Patent No. 9,693,933 in related litigation?

U.S. Patent No. 9,693,933, which covers a method for producing fentanyl compositions with reduced methyl ester impurity, has been a subject of separate, but related, litigation concerning manufacturing processes.

How do patent litigation outcomes for Subsys impact the broader opioid market?

Successful patent challenges can lead to earlier generic entry, increasing drug affordability and potentially mitigating some aspects of high drug costs, though the ethical considerations surrounding opioid products remain a separate, significant issue.

Citations

[1] United States District Court for the District of Delaware. (2018). Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. Case No. 1:18-cv-01308. [2] United States Patent and Trademark Office. (2013). U.S. Patent No. 8,551,539. [3] United States Patent and Trademark Office. (2017). U.S. Patent No. 9,693,933.